Document is current
Any future updates will be listed below
-
Authors
Nappo, G.
D’Ambra, V.
Ricci, C. https://orcid.org/0000-0002-6638-4479
Pagnanelli, M.
Rebasti, V.
Alves, G.
Crippa, S.
Rimassa, L.
Casadei, R.
Zerbi, A.
-
Funding
Funding for this research was provided by:
Alma Mater Studiorum - Università di Bologna
- License Information
-
More Information
Article History
Received: 29 January 2025
Accepted: 18 August 2025
First Online: 1 September 2025
Declarations
:
: LR received consulting fees from AbbVie, AstraZeneca, Basilea, Bayer, BMS, Eisai, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; lecture fees from AstraZeneca, Bayer, BMS, Guerbet, Incyte, Ipsen, Roche, Servier; travel expenses from AstraZeneca; and institutional research funding from AbbVie, Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Jazz Pharmaceuticals, Lilly, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, TransThera Sciences, Zymeworks. The other authors declare no conflicts of interest.
: This article is a meta-analysis of previously published studies and does not involve any new studies with human participants or animals performed by any of the authors.
: Not applicable, as this study is a meta-analysis of previously published data.
